Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Gilead Sciences, Inc.

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Prices $3.5 Billion of Senior Unsecured Notes
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Present at Upcoming Investor Engagements
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces Third Quarter 2024 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD MRK
Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces Second Quarter 2024 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.